Nabriva therapeutics plc (NBRV)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16
Cash flows from operating activities
Net loss

-23,259

-23,045

-17,795

-21,707

-20,217

-30,825

-52,825

-17,788

-13,342

-22,262

-22,269

-14,602

-15,223

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-13,599

Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash other income/expense, net

-673

-9

46

-24

27

-195

-76

-203

112

15

348

742

266

-1,279

30

-671

924

Non-cash interest income

-15

2

4

-41

13

-102

7

40

10

-

-

33

30

-50

37

21

44

Non-cash interest expense

1

140

8

144

227

-

-

-

-

-

-

-

-

-

-

-

-

Loss on extinguishment of debt

-2,757

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation and amortization expense

103

234

-83

120

125

119

129

129

133

137

146

73

76

61

73

54

45

Amortization of right-of-use assets

15

83

80

102

109

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation

1,765

1,882

4,138

1,821

1,907

1,720

1,423

767

1,244

1,194

1,662

2,192

684

562

578

825

580

Deferred income taxes

-

-

-

-

-

-

-

-

-

0

2,093

-861

178

-366

-397

-13

-18

Other, net

-22

-

-

-28

8

2

17

1

-6

-16

42

19

86

-35

35

0

1

Changes in operating assets and liabilities:
Increase in long-term receivables

-

-338

6

272

10

0

0

0

3

-

-

-17

5

-18

2

-9

15

Increase in accounts receivable, net and other receivables and prepaid expenses

2,326

-3,840

1,650

-3,042

2,650

-3,500

-149

518

1,992

1,777

-4,869

1,729

1,586

-

-

-

-

Increase in inventory

3,542

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Changes in other receivables

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,638

Increase/(decrease) in accounts payable

-2,537

1,349

307

-4,648

4,302

-1,496

768

-828

-1,413

-47

-2,343

3,186

1,789

-149

863

-3,332

2,235

Decrease in accrued expenses and other liabilities

-1,784

344

553

268

-4,374

4,605

1,279

1,169

-1,311

-1,374

1,052

-3,073

-383

783

1,701

1,059

2,491

Increase/(decrease) in other non-current liabilities

54

-84

-36

-22

-30

20

8

11

22

69

9

12

6

11

4

1

8

Increase/(decrease) in income tax liabilities

-21

-108

24

-8

18

-187

-79

-127

451

14

-11

6

-10

-

-

-

-1

Net cash used in operating activities

-28,108

-15,487

-14,657

-21,123

-20,625

-22,231

-17,132

-17,021

-16,339

-24,082

-15,047

-15,535

-14,684

-

-

-

-

Cash flows from investing activities
Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-10,879

Purchases of plant and equipment and intangible assets

72

-36

40

15

42

20

41

8

160

32

905

211

25

147

149

240

67

Changes in restricted cash

-52

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from sale of property, plant and equipment

-

-

-

-

-

-

-

-

-

0

0

0

2

-

-

-

-

Proceeds from sales of available-for-sale securities

-

-

-

-

-

-

-

-

-

-

32,500

8,000

10,000

-

-

-

-

Proceeds from sales of available-for-sale securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

10,000

12,000

3,000

Net cash used in investing activities

-20

200

15,188

-15,015

-42

-229

-4,092

-123

-160

388

31,595

7,789

9,977

-

-

-

-

Cash flows from financing activities
Proceeds from at-the-market facility

154

4,755

9,597

3,614

9,978

1,435

0

3,396

19,388

-

-

-

-

-

-

-

-

Repayments of long-term borrowings

-30,000

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,933

Proceeds from long-term debt, net of issuance costs

-

-

-

-

-

23,010

125

221

189

0

0

-1

229

-

-

-

-

Proceeds from exercise of stock options

-

-

-

-

-

-

-

-

-

0

72

1

10

26

6

208

29

Equity transaction costs

373

1,700

245

115

299

118

3,747

458

518

1,710

4,899

73

1,410

-

-

-

-

Net cash provided by (used in) financing activities

-30,219

23,395

19,252

3,749

9,679

24,327

46,378

3,159

19,059

-1,710

75,173

-73

-1,171

-

-

-

-

Effects of foreign currency translation on cash and cash equivalents

-682

-26

-120

13

27

-195

-76

-203

112

-

-

-

-

-

-

-

-

Net decrease in cash, cash equivalents and restricted cash

-59,029

8,082

19,663

-32,376

-10,961

1,672

25,078

-14,188

2,672

-

-

-

-

-

-

-

-

Effects of foreign currency translation on cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

266

-

-

-

-

Net cash provided by (used in) financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

29

Effects of foreign currency translation on cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

924

Net (decrease) increase in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-5,612

-

-2,715

-1,954

-6,993

Supplemental disclosure of cash flow information:
Interest paid

1,022

825

626

626

483

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from at-the-market facility in accounts receivable, net and other receivables

164

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Equity transaction costs incurred in prior periods and paid in current period

-

-

-

-

-

-

-

0

28

-

-

-

-

-

-

-

-

Equity transaction costs included in accounts payable and accrued expenses

217

173

-116

478

20

11

-10

-307

426

-

-

-

-

-

-

-

-